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Background: Previous studies showed functional improvement in stable patients with schizophrenia treated with
risperidone long-acting injection (LAI). We therefore re-investigated functional improvement with risperidone LAI in
remitted patients, in comparison with stable patients. The study was conducted in real-life conditions because of the
high heterogeneity of the patients’ situations.
Method: This was a multi-centre, prospective observational cohort study involving adult schizophrenia-spectrum
chronic patients who were previously treated with risperidone LAI for 6 months. Remission was evaluated using the
consensus criteria proposed by the Remission in Schizophrenia Working Group (RSWG). The primary endpoint was
global functioning (assessed with the Global Assessment of Functioning scale, GAF) after one year of treatment.
Social functioning was a secondary outcome.
Results: The analysis included 1490 patients. Attrition rate was 9.1 % at the end of the study. 27.7 % of patients
were in remission after one year of risperidone LAI treatment. The mean GAF rating score (62.5 ± 1.5) was higher
than the cut-off previously used to identify patients with satisfactory functioning (60) and significantly higher than
the mean GAF score in stable, non-remitted patients (48.3, p < 0.001). Social functioning was also high in remitted
patients (21.0 ± 3.6 vs. 17.2 ± 3.7 in non-remitted patients, p < 0.001).
Conclusion: The results clearly show that after one year of treatment with risperidone LAI, RSWG-remitted patients
have a high level of global functioning, which is significantly higher than in stable, non-remitted patients. Social
functioning was also higher in remitted patients as compared with stable, non-remitted patients.
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Personal hygiene and clothing
Housekeeping Housework, laundry, shopping (food, etc.)
Familial and social
integration




Ability to get information and fulfill administrative




Ability to engage in social, creative or recreational
activities (attendance at social groups, foundations,
clubs or groups of mutual aid)
Managing
stigmatization
Knowing one’s disability, asserting rights,
withstanding criticisms
Workinga Ability to project into professional life according
to the degree of disability. Having a job in
a protected or ordinary environment
Scale. 1: do not do – 2: neglect – 3: do, but with efforts – 4: do without effort
aScale. 1: not applicable – 2: projects of professional life – 3: in training for
working rhythms – 4: has a job in a protected or ordinary environment
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A long-acting injectable (LAI) form of the atypical anti-
psychotic risperidone was introduced 12 years ago to re-
duce the risk of partial compliance and adverse outcomes
in patients with schizophrenia [1–3]. The symptomatic effi-
cacy of risperidone LAI was evaluated using the consensus
criteria proposed by the Remission in Schizophrenia Work-
ing Group (RSWG; a state of no greater than low-to-mild
intensity in core psychotic symptoms, sustained for a mini-
mum duration of 6 months) [4]. These studies showed
higher remission rates with risperidone LAI (21–45 %)
[5–8] as compared with oral antipsychotics (between
6.3 % for risperidone and 12.4 % for olanzapine) [9].
The ultimate goal of treatment in schizophrenia is re-
covery, i.e., patients regaining functioning and participat-
ing in social and vocational opportunities [10]. Previous
interventional studies showed functional improvement
under risperidone LAI treatment in patients with non-
acute, stable schizophrenia or schizoaffective disorder
[11–14]. On the other hand, a post-hoc analysis of the
StoRMi (Switch To Risperidone Microspheres) interven-
tional trial showed both, global functioning recovery and
RSWG-remission in 21 % of patients under risperidone
LAI [15]. Finally, the therapeutic benefit of drugs should
be re-examined in real-life conditions because of the
high heterogeneity of the patients’ situations.
Taking all the above elements together, we re-
investigated functional improvement with risperidone
LAI in RSWG-remitted patients, in comparison with
stable patients. The study was conducted in real-life
conditions because of the high heterogeneity of the pa-
tients’ situations (the EVeREST, EValuation of function-
ing in REmission after Symptomatic Treatment, study).
Although the Global Assessment of Functioning (GAF)
scale is widely used to evaluate functioning, we decided
to use an additional scale, to evaluate social skills and
social roles (“ad hoc” scale shown in Table 1).Methods
Study design
This was a multi-centre, prospective observational cohort
study of 1554 adult schizophrenia patients who were initi-
ated to risperidone LAI treatment 5 to 7 months before the
beginning of the study (Fig. 1). Data was communi-
cated by 381 French psychiatrists, between July and
December 2008. The study was sponsored by Janssen Cilag
(Issy les Moulineaux, France). C2R (Paris, France) was in
charge of the setting-up of the study and provided access
to the TVF database of CEGEDIM (Centre de gestion et de
Documentation de l’Information Médicale; Management
and documentation centre of medical information,
Boulogne-Billancourt, France). STATITEC (Labege, France)
was in charge of the statistical analysis.The study was declared to the CNIL (Commission
Nationale de l’Informatique et des Libertés; National Com-
mittee of informatics and Freedom) and authorized by the
CCTIRS (Comité Consultatif pour le Traitement de l’In-
formation en matière de Recherche dans le domaine de la
Santé; Advisory Committee for the Evaluation of Informa-
tion in the field of Health Research) [16]. Patients were in-
formed about the study by the participant psychiatrists
and gave consent to communicate data. The study also
agreed with the Helsinki Declaration (1975, revised 1983)
(World Medical Association Declaration of Helsinki: http://
www.wma.net/en/30publications/10policies/b3/index.html).
The number of French psychiatrists practicing in a
public or private structures for management of psychotic
patients, including patients with schizophrenia, was esti-
mated at 5500 [17]. A list of 1500 physicians, balanced
and stratified by region, was selected at random by using
the TVF database to obtain a representative sample at
the national level. This database, which is commonly
used by French Health Services, is under the control of
the CNIL. The psychiatrists interested in participating
were contacted by regular mail to obtain a written agree-
ment to take part in the study and certify their know-
ledge in safety procedures concerning serious adverse
events.
The study included adult patients (18–65 years old)
diagnosed as schizophreniform or schizophrenia dis-
order (DSM-IV criteria) who had been under treat-
ment with risperidone LAI for five to seven months
and who had decided to continue treatment (Fig. 1,
M-6). To ensure representativeness of the studied
population, only the first three consulting patients
Fig. 1 Clinical study flow diagram. Number of patients is given with dropout numbers in brackets. M-6 (risperidone LAI initiation, 6 months before
inclusion), M0 (month 0, first evaluation visit), M3 (month 3, follow-up visit), M6 (month 6, end of study)
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and included three visits (Fig. 1): visit 1 (M0, month
0; 6 months after risperidone LAI initiation), visit 2
(M3, month 3; 9 months after risperidone LAI initi-
ation), and visit 3 (M6, month 6; at the end of the
study, 12 months after the initiation of risperidone
LAI treatment).
At visit 1, 70.8 % of patients had an adjunctive drug
treatment (anxiolytics 57.6 % of patients, hypnotics
41.8 %, antidepressants 30 %, antiparkinsonians 21.3 %
and mood stabilizers 21.0 %). Moreover, 55.7 % of pa-
tients received psychosocial interventions.
Data collection
The participating psychiatrists collected the following
patients’ information (in case report forms):
➢ At M0
✓ Demographic aspects
✓ History of schizophrenia or schizophreniform
disorder
✓ Actual clinical and therapeutic aspects, including:
 Treatment follow-up (number of missed injections,
date and reason for discontinuation of treatment, if
necessary)
 PANSS (positive and negative symptom scale)
core of psychotic symptoms
 Functioning, assessed by the Global Assessment of
Functioning (GAF) scale and by a Social
Functioning in Schizophrenia “ad hoc” scale
(Table 1). This latter evaluates social skills (4
items) and social roles (3 items).
 Clinical Global Impression (CGI) - Severity and
improvement scales
➢ At M3 (3 months ± 15 days)
✓ Clinical and therapeutic aspects, including:
 Treatment follow-up (number of missed injections,
date and reason for discontinuation of treatment, if
necessary) Clinical Global Impression - Severity scale (CGI-S)
 Adverse events (AE)
➢ At M6 (6 months ± 1 month) or termination of the
study
✓ Clinical and therapeutic aspects, including:
 Treatment follow-up (number of missed injections,
date and reason for discontinuation of treatment, if
necessary)
 PANSS core psychotic symptoms
 Functioning, assessed by the GAF scale and by an
ad hoc Social Functioning in Schizophrenia scale
(Table 1).





Global functioning in patients remitted (N = 374) and
non-remitted (N = 976) at M6. Remission was evaluated
using the consensus RSWG criteria, i.e.,: a state of no
greater than “mild” intensity in core psychotic symptoms,
sustained for a minimum duration of six months [4]. As
per DSM-IV (see ref. [18]), a score of 60 out of 100 was
taken as a cut-off to identify patients with moderate to se-
vere impairment in functioning (GAF score ≤ 60, repre-
senting some mild difficulty in socio-professional activities
or satisfactory activity).
Missing data concerning PANSS and/or GAF data at
M0 and/or M6 were considered as major deviations to
the protocol.
Secondary endpoints
➢ Social functioning: evolution, comparison of social
functioning between remitted and non-remitted
patients at M6
➢ Social abilities as a function of psychosocial measures
➢ AE in “real-life”
Table 2 Demographic aspects and medical history of the
included patients
Month 0 Month 6
Number of patients 1490 1354
Age (years) 36.7 ± 0.3 36.8 ± 10.9
Sex (% males) 65.2 % 64.6 %
Marital status (% patients)
Married or cohabiting 17.2 % 16.9 %
Single 68.9 % 68.8 %
Divorced, widowed, separated 13.9 % 14.3 %
Patients with children (% patients) 27.6 % 27.8 %
Accommodation (% patients)
Independent housing 62.6 63.1
Dependent housing 20.9 20.7
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Adverse events (AE) were reported in the case report
forms beginning at the inclusion of the study (M0) until
one month after the study was finished. AE appearing
with a delay that was chronologically consistent with the
administration of the product were considered to be re-
lated to risperidone LAI treatment when a causal rela-
tionship was possible, likely, or very likely:
➢ Possible relation: The AE can also be attributed to a
concomitant disease or other medications. Causality
cannot be excluded.
➢ Likely relation: The attribution to a concomitant
disease or the other medications does not seem
likely, and risperidone LAI treatment discontinuation
led to the disappearance of the AE or improved
symptoms.
➢ Very likely relation: The AE cannot be attributed to
a concomitant disease or other medication. The time
to onset was chronologically very consistent with the
administration of risperidone LAI, risperidone LAI
treatment discontinuation led to the disappearance
of the AE or improved symptoms, and risperidone
LAI re-administration led to a recurrence of the
same AE symptoms.Homeless housing 1.3 % 1.3 %
Hotel 0.9 % 1.0 %
Institutional center/Foundation 8.9 % 8.7 %
Retiring home 0.5 % 0.6 %
Other 4.8 % 4.7 %
Current employment status (% patients)Patient population size
We estimated that an initial sample size of 1500 patients
was required to have ≥80 % power in detecting a differ-
ence in outcome of ≥10 % (if the two populations were
relatively similar in size and that the smallest comprises
35 % or more of the total survey population).Employee 12.2 % 11.7 %
Student or in training 6.3 % 5.9 %
Help Center for Labor 7.2 % 7.3 %
Unemployed or retired 9.6 % 9.5 %
Freelancer 1.0 % 1.1 %
Disabled or sick leave for psychiatric disorder 56.4 % 57.0 %
Status unknown 0.8 % 0.9 %
Other 6.5 % 6.5 %
Psychiatric historyStatistics
Statistical comparisons between the two groups of pa-
tients were done by using the following tests: Mantel-
Haenszel Chi-2 test for stratified categorical variables,
Chi-2 of the homogeneity test for non-stratified categor-
ical variables, and the non-parametric Wilcoxon test for
continuous variables. The statistical level of significance
was accepted for p values < 0.05. Values are presented as
mean ± SEM (standard error of the mean).DSM-IV diagnostic (% patients)
Schizophrenia 76.4 % 76.4 %
Schizophreniform disorder 23.6 % 23.6 %
Chronicity (% patients)
≤ 5 years 30.7 % 30.3 %
> 5 and≤ 10 years 31.8 % 31.9 %
> 10 and≤ 15 years 16.6 % 16.6 %
>15 years 20.8 % 21.2 %
Values are given as mean ± SEM or as % of patients. M0, month 0 (inclusion).
M6, month 6 (end of study)Results
The study included 1491 patients at M0 (security safety
analysis set). One patient was excluded because of a
major protocol deviation (no PANSS or GAF data avail-
able from M0 or M6). Of the remaining 1490 patients,
1408 (94.5 %) and 1354 (90.9 %) were seen again at M3
and M6, respectively. The main reason for discontinu-
ation was patients’ decision (68.6 %). Follow-up time
was 5.6 ± 1.0 (mean ± SD).Demographic aspects and medical history of the
participating patients
Table 2 shows demography and psychiatric history of the
patients at M0 and M6. At M0, patients were mostly
men (65.2 %) and their average age was 36.7 ± 0.3 years.
Most of them were single (69 % of patients) and without
children (72 % of patients). More than half were on dis-
ability or sick leave for psychiatric disorders (56 % of pa-
tients). More than three-quarters of patients (76.4 %) were
Table 3 Evolution of functional performance between M0 and
M6
M0 M6 M6-M0 p
(N = 1490) (N = 1354)
GAF rating scorea 46.4 ± 0.54 52.2 ± 0.67 5.8 ± 0.45 < 0.001
Social functioning
rating scoreb
18.3 ± 0.11 20.2 ± 0.12 1.9 ± 0.10 < 0.001
Social skills 11.4 ± 0.06 12.5 ± 0.07 1.1 ± 0.07 < 0.001
Social roles 6.90 ± 0.05 7.73 ± 0.06 0.83 ± 0.05 < 0.001
Values are given as mean ± SEM. M0, month 0 (inclusion). M6, month 6 (end
of study)
aMaximum GAF rating score = 100
bSocial functioning rating scores = total (from 7 to 28), social skills (from 4 to 6)
and social roles (from 3 to 12)
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DSM-IV criteria (Table 2). The disease duration was ≤
10 years for 62.5 % of the patients.
Clinical assessment
Figure 2 shows PANSS core psychotic symptom scores at
M0 and M6. At M0, four mean rating score values were of
moderate severity (conceptual disorganization, blunted
affect, passive/apathetic social withdrawal, lack of spon-
taneity and flow of conversation). At M6, all mean rating
score were of mild severity.
Table 3 shows that the mean global functioning (GAF
rating score) significantly improved (p < 0.001) by 5.8 ±
0.45 from M0 (46.4) to M6 (52.2). Figure 3 shows fre-
quency distributions for global functioning scores at M0
and M6. The percentage of high functioning patients
(GAF rating scores >60) increased from 25.2 % at M0 to
42.1 % at M6 (p < 0.0001).
Social functioning significantly improved between M0
and M6 (Table 3). Thus, mean social functioning total
scores significantly increased by 1.9 ± 1.0 from 18.3 to
20.2 (p < 0.001). This resulted from a significant increase
(p < 0.001) in the rating scores of both social skills and
social roles (Table 3).
CGI rating scores showed a tendency to decrease
throughout the observation period. The average scale
score “CGI - Severity” slightly decreased from 4.0 ±
0.032 at M0, to 3.6 ± 0.032 at M3 and 3.3 ± 0.035 at
M6, and the average scale score “CGI - Improvement”
evolved from 2.4 ± 0.022 at M0 to 2.2 ± 0.027 at M6.
Consistently, the percentage of patients with CGI se-
verity scores ≥ 5 (categorized “markedly ill”, “severely
ill” or “among the most extremely ill patients”) de-
creased from 37.9 % at M0, to 21.3 % at M3 and to
18.7 % at M6.
Other treatments
The majority of the patients (70.8 %) had another psycho-
tropic medication, particularly anxiolytics (57.6 % ofFig. 2 PANSS core psychotic symptom scores at M0 and M6patients), hypnotics (41.8 %) and sedatives (27.0 %). This
propensity of patients for other psychotropic medications
remained high at M3 (64.6 % of patients) and M6 (62.8 %).
Concerning psychosocial measures, non-specific inter-
vention support was implemented for more than half of
the patients (55.7 %, 53.5 % and 55.9 % at M0, M3 and
M6, respectively).
Remission status according to the PANSS scale (core
psychotic symptoms)
Figure 4 shows that 27.7 % of the patients were in remis-
sion at M6, according to the RSWG criteria. This com-
pares well with the 29.9 % of patients with “mild”
intensity in core psychotic symptoms at M0, but not
with the 58.4 % of patients with “mild” intensity in core
psychotic symptoms at M6 (Fig. 4).
At the inclusion visit, patients with a remission of
schizophrenia had the following characteristics, as com-
pared with non-remitted patients:
➢ Better global functioning (GAF rating score = 53.8 ±
1.4 vs. 43.6 ± 0.54, p < 0.001)
➢ A better social functioning profile (total score = 21.0
± 0.19 vs. 17.2 ± 0.12, p < 0.001)Fig. 3 Frequency distributions for global functioning scores at
M0 and M6
Table 4 Functional performance at M6, in remitted schizophrenic
patients (RSWG-criteria)
Remitted patients Non-remitted patients p
Number of
patients
374 (27.7 %) 976 (72.3 %)
GAF total rating
scorea





21.0 ± 0.19 17.2 ± 0.12 <0.001
Social skills
rating scoreb
12.8 ± 0.11 10.8 ± 0.07 <0.001
Social roles
rating scoreb
8.2 ± 0.10 6.4 ± 0.06 <0.001
Values are given as mean ± SEM or as % of patients. M6, month 6 (end of study)
aMaximum GAF rating score = 100
bSocial functioning rating scores = total (from 7 to 28), social skills (from 4 to
16) and social roles (from 3 to 12)
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0.032)
➢ A better CGI improvement score (1.9 ± 0.036 vs. 2.6
± 0.022)
Functional performance in remitted schizophrenia
patients
Table 4 shows the functional performance at M6 in pa-
tients with remission of schizophrenia. The global function-
ing rating score was 62.5 ± 1.5 (the main objective of the
study). This was significantly higher than the mean GAF
score in non-remitted patients (48.3 ± 0.74, p < 0.001). So-
cial functioning rating scores were also significantly higher
(p < 0.001) in remitted patients (Table 4).
Adverse events
Risperidone LAI was well tolerated. Only 88 of 1491 pa-
tients (6 %) reported at least one AE (anxiety, insomnia,
depression, headache). The investigator considered that 69
AE (18 severe) were related to risperidone LAI treatment.
Discussion
We analysed a large sample in real-life conditions, with
a long follow-up and low attrition rate. After one year of
risperidone LAI treatment, 27.7 % of the study’s patients
were in RSWG-remission. This high remission rate was
quantitatively similar to that observed in the StoRMi
trial (33 %) [15] and higher than that observed with oral
risperidone in the CATIE study (6.3 %) [9]. This result
can be likely explained by non-adherence to long-term
oral medication regimes, which is one of the most sig-
nificant therapeutic issues in the therapy of schizophre-
nia and related disorders [3].Fig. 4 Remission status according to the PANSS scale (core psychotic
symptoms). RSWG criteria include: a score≤ 3 for the 8 items of the
PANSS scale maintained for at least 6 months. This time criterion could
not be evaluated at M0 due to the lack of data before inclusion.
However, the PANSS score was first evaluated at M0 and then
6 months later at M6, so it was possible to evaluate the proportion of
patients who met the RSWG criteria at M6Previous studies showed functional improvement under
risperidone LAI treatment in patients with stable schizo-
phrenia or schizoaffective disorder [11–14]. On the other
hand, the mean GAF rating score in remitted patients
(62.5) was higher than the cut-off previously used to iden-
tify patients with satisfactory functioning (60) and sig-
nificantly higher than the mean GAF score in stable,
non-remitted patients (48.3). Our study thus clearly
shows that further improvement can be obtained in
remitted patients (as compared with stable, non-
remitted patients).
Achieving functional recovery is a key goal for clinicians
treating patients with schizophrenia, but patients with
schizophrenia and their families are also concerned with
the regain of a patient’s ability to act or to give meaning to
his or her life (empowerment) and social functioning
(managing daily life, social and/or professional skills). It
seems, therefore, appropriate to include social functioning
as a supplementary criterion of recovery.
Our study suggested that social functioning is also
higher in remitted patients as compared with non-
remitted patients. However, our scale should be vali-
dated in further studies and/or other social functioning
scales should be used to confirm this point.
It is important to mention that patients under risperi-
done LAI continued to improve between their 6 and
12 months of treatment. Thus, the percentage of pa-
tients with mild intensity in core psychotic symptoms
(PANSS) increased from 29.9 to 58.4 % between 6 and
12 months treatment. In the same period, the percentage
of high functioning patients (GAF rating scores >60) in-
creased from 25.2 to 42.1 %. The percentage of patients
with CGI severity scores ≥ 5 (categorized “markedly ill”,
“severely ill” or “among the most extremely ill patients”)
decreased from 37.9 % at M0, to 21.3 % at M3 and to
18.7 % at M6. These results illustrate the importance of
Giraud-Baro et al. BMC Psychiatry  (2016) 16:8 Page 7 of 8long-acting antipsychotic treatment for ensuring a con-
tinuity of symptomatic and functional remission.
Risperidone LAI should be investigated for other recov-
ery aspects of schizophrenia, since patients in RSWG-
remission have a better cognitive outcome [19, 20] and
quality of life [21, 22], but may perceive a decreased sense
of wellbeing [23]. In addition, Rocca et al. [24] reported
that second generation antipsychotic use predicts better
social functioning and better executive functions.
Limitations of the study
The results apply to chronic patients, two-thirds of them
with over 5 years of the disorder. The scope of our study
does not allow for a certain conclusion about symptom im-
provement being due to risperidone specifically, since there
is no information about other treatments. Furthermore, the
choice of a GAF of 60 as cut-off for functional remission
was frequently used, but it is arbitrary. Finally, the Social
Functioning in Schizophrenia is an ad hoc scale. Such limi-
tations should be taken into consideration by future studies.
Conclusions
Our results clearly show that after one year of treatment
with risperidone LAI, RSWG-remitted patients have a high
level of global functioning, which is significantly higher than
in stable, non-remitted patients. Social functioning was also
higher in remitted patients as compared with stable, non-
remitted patients. This latter should be confirmed in further
studies using validated social functioning scales.
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